<DOC>
	<DOCNO>NCT00510692</DOCNO>
	<brief_summary>This purpose study investigate whether number size rectal polyp reduce patient Familial Adenomatous Polyposis ( FAP ) use highly-purified form naturally occur substance , omega-3 fatty acid , eicosapentaenoic acid ( EPA ) .</brief_summary>
	<brief_title>Chemoprevention Trial Familial Adenomatous Polyposis ( FAP ) Coli Using EPA</brief_title>
	<detailed_description>It find people consume large amount oily fish tend low risk develop colon cancer . This thought due omega-3 fatty acid present oily fish , one EPA . The effect take 99 % pure form EPA ( 2g per day ) compare placebo capsule number size polyp rectum six month period investigate . FAP inherited susceptibility diffuse colorectal adenoma colorectal carcinoma , occur close 100 % unresected colon . It cause germline mutation Adenomatous Polyposis Coli ( APC ) gene locate long arm chromosome 5 . To prevent cancer development recommend patient FAP undergo colectomy ileo-anal ileo-rectal anastomosis ( colectomy end-ileostomy ) socially convenient time polyp progression malignancy age 25 . Patients attenuate FAP phenotype , often associate mutation 5 ' terminus ( exon 4 proximally ) , few polyp may often delay colectomy . Patients ileo-rectal anastomosis still susceptible polyp formation remain rectal stump require 6 monthly check-ups flexible sigmoidoscope removal polyp develop . Therefore , effective chemopreventative agent favourable side-effect profile would benefit FAP patient ileo-rectal anastomosis ( IRA ) recurrent rectal polyp addition young adult prefer delay colectomy . If agent effective FAP patient prevention colonic polyp , may also benefit large population patient sporadic colorectal adenomatous polyp also risk colorectal cancer . Colorectal polyps thought , least part , arise imbalance level cell proliferation apoptosis ( natural cell death ) colonic mucosa . It suggest omega-3 polyunsaturated fatty acid ( PUFAs ) fish oil manipulate high level colonic-mucosal cell proliferation rate associate colonic adenoma . The rationale trial base increase evidence link inflammatory process development number cancer , include bowel cancer . This focused attention role inflammatory mediator development cancer . In particular , family eicosanoids ( include 2-series prostaglandin , 4-series leukotrienes thromboxanes ) produce conversion omega-6 PUFA , arachidonic acid , via cyclo-oxygenase-2 ( COX-2 ) believe contribute physiological process inflammation development tumour . Prostaglandin E2 , product conversion arachidonic acid via COX-2 pathway , implicate tumourigenesis : 1. promotion angiogenesis 2. anti-apoptotic property 3. increase expression matrix metalloproteinases hence ability tumour cell undergo metastasis 4. alter cytokine expression profile cell . The class eicosanoid synthesise depend PUFA substrate . Whilst arachidonic acid convert 2-series prostaglandin 4-series leukotrienes , EPA convert 3-series prostaglandin 5-series leukotrienes . Overall , latter eicosanoids less potent inflammatory mediator derive arachidonic acid . Increasing daily intake EPA , omega-3 PUFA analogue arachidonic acid , alters balance cell content fatty acid . This result reduce production active inflammatory/tumourigenic product arachidonic acid metabolism . This supported result recent work St George 's Hospital Medical School , London . In patient history colonic adenoma , daily dose highly purify , free-fatty acid form EPA produce significant reduction cell proliferation increase apoptosis colonic mucosa . This preparation EPA proprietary name `` Alfa '' refer EPA . This propose study base upon randomise , placebo-controlled National Cancer Institute sponsor study three group FAP patient assign one two dos celecoxib ( COX-2 inhibitor ) placebo . The result show reduction polyp burden group take high ( 400mg twice daily ( bd ) ) dose . However , evidence suggest COX-2 inhibitor carry significant potential side-effects . Adopting similar design , EPA substitute celecoxib randomise , placebo-controlled trial , compare 2g EPA placebo , reduction polyp burden primary objective .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<criteria>Subjects must know diagnosis Familial Adenomatous Polyposis ( FAP ) previous colectomy ileorectal anastomosis . Males female age 18 If participant female child bear potential , agree participate study provide write informed consent , use adequate contraception ( e.g . abstinence , condom , Intrauterine device ( IUD ) , birth control pill , diaphragm spermicidal gel combination ) since last menses use adequate contraception study , lactate , agree undergo serum pregnancy test baseline month 6 . Sexually active male must agree use accepted method contraception . Rectal polyp status : subject endoscopically assessable rectal segment . Subjects must show willingness abstain regular use nonsteroidal antiinflammatory medication duration study . A cardioprotective dose aspirin ( 75mg ) permit . Subjects must provide write informed consent participate . Subjects must assessable rectal polyp post baseline flexible sigmoidoscopy . Subjects must follow rectal polyp burden conclusion baseline endoscopy : Rectum 3 quantifiable polyp â‰¥2mm diameter In rectum quantifiable polyp define within composite `` cloverleaf '' photograph include tattoo . Subjects due undergo anticipated colectomy within 8 month randomisation History invasive carcinoma past 5 year resect Dukes ' A/B1 colon cancer resect nonmelanomatous skin cancer Partial complete colectomy within 12 month prior enrolment . History pelvic radiation Subjects allergic fish Subjects diabetes mellitus Subjects pregnant breastfeeding Subjects take aspirin nonsteroidal antiinflammatory drug regular basis low dose ( 75 mg ) cardioprotective dose . Subjects aspirinsensitive asthma Subjects suffer haemorrhagic disorder Subjects take warfarin anticoagulant Subjects significant abnormality screen blood test Subjects take lipid lower medication Subjects gastrointestinal malabsorptive disease Subjects know prior coagulopathy Subjects uncontrolled hypercholesterolaemia Subjects take fishoil supplement ( e.g . cod liver oil ) unwilling stop duration study . Subjects previously take fish oil must washout period 1 month prior study enrolment . Subjects deem mentally incompetent , history anorexia nervosa bulimia Subjects history alcohol drug abuse , include laxative abuse would render subject unreliable . Subjects consider physician unlikely able comply protocol . Subjects take part experimental drug study precede 3 month . Subjects positive pregnancy test within 14 day prior baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>EPA</keyword>
	<keyword>EPA 99 %</keyword>
	<keyword>Fatty acid</keyword>
	<keyword>omega-3</keyword>
	<keyword>apoptosis</keyword>
	<keyword>cell proliferation</keyword>
	<keyword>colonic mucosa</keyword>
	<keyword>polyp</keyword>
	<keyword>Familial Adenomatous Polyposis Coli</keyword>
	<keyword>FAP</keyword>
	<keyword>resolvin</keyword>
	<keyword>Ileo-rectal anastomosis</keyword>
	<keyword>IRA</keyword>
	<keyword>PUFA</keyword>
	<keyword>Endoscopy</keyword>
</DOC>